$9.6 Million Series A Primes Wesper to Disrupt The Sleep Health Industry

2022-11-21
With FDA clearance and insurance coverage, Wesper has crafted a clinical-grade solution to deliver sleep medicine to the masses.
NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Wesper, the first clinical-grade FDA-cleared wireless home sleep lab, announced a $9.6 million Series A round to accelerate growth and revenue as well as continue to develop industry-leading diagnostic sensing technology. The round included participation from Valor Equity Partners, Breyer Capital, Spark Capital, as well as angel investors from leading health-tech firms.
Wesper's wireless biometric sensors and algorithms enable at-home medical diagnosis with professional services and ongoing measurement before, during, and after treatment. With Wesper, users have access to customized, professional guidance from sleep specialists and physicians without having to leave their homes.
"Wesper is at the forefront of revolutionizing the sleep industry through superior access to biometric data and an increased focus on patient experience, working to ensure that every patient who suffers from sleep problems gets the care they deserve," said Amir Reuveny, Founder and CEO of Wesper.
With this new funding round, Wesper will build partnerships with sleep centers, dental clinics and coaches to bring Wesper to patients across the US. Through FDA clearance for assistance with HSAT (home sleep apnea testing), clinics can use Wesper's superior algorithms, biometric data, and unparalleled patient experience to help more patients.
The company has on-boarded key medical institutions and is set to expand its presence in the sleep clinic space. This includes expanding its medical advisor network and forging strategic partnerships with key players such as hospitals, sleep labs, and insurance providers.
"Improving your sleep used to be a very lonely and complicated process, and we are here to change that," says Dr. Chelsie Rohrscheib, the head sleep expert at Wesper. "We are committed to our users every step of the way to getting high-quality sleep."
About Wesper
Wesper is a doctor-supervised sleep health program that offers a powerful clinical-grade system designed to get you the care you need. Meet with sleep experts and board-certified physicians to review your comprehensive sleep data and get a tailor-made treatment plan, all from the comfort of your own bed. With a 95.1% correlation to a sleep lab, Wesper measures longitudinally sleep position, snoring, oxygen desaturation, apnea events, breathing quality, pulse rate, and much more.
SOURCE Wesper
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。